Cybin (HELP) EBITDA Margin (2020 - 2024)
Cybin (HELP) reported EBITDA Margin of 86.96% for Q4 2024, down 95490.0% on a YoY basis from N/an in Q1 2024, and down 110.02% quarter-over-quarter from 867.94% in Q4 2023.
Cybin (HELP) EBITDA Margin (2020 - 2024) Analysis & Trends
Cybin has reported EBITDA Margin for 3 years, with the latest figure at 86.96% in Q4 2024.
- For the quarter ending Q4 2024, EBITDA Margin fell 95490.0% year-over-year to 86.96%; the trailing twelve-month figure through Dec 2024 stood at 675.14% (changed N/A YoY), and the FY2021 full-year result was 3468.4%, changed N/A from the prior year.
- EBITDA Margin for Q4 2024 stood at 86.96%, down from 867.94% in the prior quarter.
- The five-year high for EBITDA Margin was 867.94% in Q4 2023, with the low at 504.98% in Q2 2020.
- Historically, EBITDA Margin has averaged 92.0% across 3 years, with a median of 86.96% in 2024.
- The largest YoY upside for EBITDA Margin was 95490 bps in 2024 against a maximum downside of 95490 bps in 2024.
- Cybin's EBITDA Margin stood at 504.98% in 2020, then jumped by 272 bps to 867.94% in 2023, then tumbled by 110 bps to 86.96% in 2024.
- The last three EBITDA Margin figures came in at 86.96% (Q4 2024), 867.94% (Q4 2023), and 504.98% (Q2 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -86.96% |
| Dec 31, 2023 | 867.94% |
| Jun 30, 2020 | -504.98% |